series-a
Stage
1
Investors
About
Veloxis Pharmaceuticals develops specialty pharmaceutical therapies focused on transplant and immunocompromised patients, aiming to improve outcomes in transplant medicine. It operates as a subsidiary of Asahi Kasei Corporation, advancing treatments for transplant care and immunosuppression.
Explore Veloxis Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.